Skip to main content

Claforan Side Effects

Generic name: cefotaxime

Medically reviewed by Drugs.com. Last updated on May 28, 2023.

Note: This document contains side effect information about cefotaxime. Some dosage forms listed on this page may not apply to the brand name Claforan.

Applies to cefotaxime: injection powder for solution.

Serious side effects of Claforan

Along with its needed effects, cefotaxime (the active ingredient contained in Claforan) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking cefotaxime:

Less common

Rare

Incidence not known

Other side effects of Claforan

Some side effects of cefotaxime may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to cefotaxime: injectable powder for injection, intravenous solution.

General

The most commonly reported side effects include injection site inflammation, pain, induration, and tenderness.[Ref]

Local

Injection site inflammation occurred with IV administration. Pain, induration, and tenderness occurred with IM administration.[Ref]

Common (1% to 10%): Injection site inflammation, pain, induration, tenderness

Postmarketing reports: Phlebitis, thrombophlebitis[Ref]

Gastrointestinal

Common (1% to 10%): Colitis, diarrhea, nausea, vomiting

Frequency not reported: Pseudomembranous colitis, abdominal pain[Ref]

Signs/symptoms of pseudomembranous colitis/Clostridium difficile infection may occur during or after treatment.[Ref]

Dermatologic

Common (1% to 10%): Rash/skin rash, pruritus

Uncommon (0.1% to 1%): Urticaria

Frequency not reported: Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme

Postmarketing reports: Bullous skin reactions, acute generalized exanthematous pustulosis (AGEP)[Ref]

Hematologic

Thrombocytopenia was reported, but usually was rapidly reversible upon discontinuation.[Ref]

Common (1% to 10%): Eosinophilia

Uncommon (0.1% to 1%): Leukopenia, thrombocytopenia

Frequency not reported: Neutropenia, transient leukopenia, granulocytopenia, hemolytic anemia, agranulocytosis, positive direct Coombs' tests

Postmarketing reports: Hemolytic anemia, aplastic anemia, pancytopenia, bone marrow failure[Ref]

Other

Common (1% to 10%): Fever

Uncommon (0.1% to 1%): Drug fever

Postmarketing reports: Malaise, superinfection, candidiasis, shivering, systemic reactions to lidocaine, false-positive test for urinary glucose[Ref]

Hepatic

Uncommon (0.1% to 1%): Transient AST, ALT, GGT, bilirubin, and alkaline phosphatase level elevations

Frequency not reported: Hepatitis, jaundice

Postmarketing reports: Cholestasis, hepatic dysfunction[Ref]

Nervous system

Uncommon (0.1% to 1%): Convulsions

Frequency not reported: Headache, dizziness, encephalopathy, impaired consciousness, abnormal movements

Postmarketing reports: Seizures[Ref]

Immunologic

Uncommon (0.1% to 1%): Jarisch-Herxheimer reaction[Ref]

Hypersensitivity

Postmarketing reports: Anaphylactic reaction, anaphylactic shock, angioedema, allergic reactions[Ref]

Genitourinary

Frequency not reported: Moniliasis, vaginitis[Ref]

Renal

Frequency not reported: Transient blood urea nitrogen level elevations

Postmarketing reports: Interstitial nephritis, transient creatinine elevations, acute renal failure[Ref]

Respiratory

Frequency not reported: Difficulty breathing

Postmarketing reports: Bronchospasm[Ref]

Metabolic

Frequency not reported: Transient lactate dehydrogenase elevations[Ref]

Musculoskeletal

Frequency not reported: Joint discomfort[Ref]

Cardiovascular

Postmarketing reports: Potentially fatal arrhythmias, shock, hemorrhage[Ref]

References

1. Product Information. Claforan (cefotaxime). Hoechst Marion Roussel. 2002;PROD.

2. Cerner Multum, Inc. UK Summary of Product Characteristics.

3. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.